SONN Stock Overview
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action.
Sonnet BioTherapeutics Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.30|
|52 Week High||US$2.07|
|52 Week Low||US$0.23|
|1 Month Change||2.44%|
|3 Month Change||15.59%|
|1 Year Change||-69.44%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-95.28%|
Recent News & Updates
Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Sonnet BioTherapeutics (NASDAQ:SONN) said a phase 1b/2a trial of SON-080 was authorized to begin in Australia in patients with persistent chemotherapy-induced peripheral neuropathy (CIPN). Peripheral neuropathy is damage to the nerves outside the brain and spinal cord (peripheral nerves) causing weakness and pain, usually in the hands and feet. It can also affect digestion, urination and circulation. Chemotherapy can also cause peripheral nerve damage in patients. SON-080 is a proprietary version of recombinant human Interleukin-6 (rhIL-6), the company noted in a July 22 press release. The study, dubbed SB211, is aimed to provide safety data compared to previous IL-6 products, along with preliminary efficacy. "Interleukin-6 has been extensively studied in cancer patients in the past, so the use of SON-080 in CIPN is expected to provide similar safety, PK, and PD results at low doses," said Sonnet's Chief Medical Officer Richard Kenney. The company noted that recruitment has begun and dosing is expected to begin imminently.
We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|SONN||US Biotechs||US Market|
Return vs Industry: SONN underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: SONN underperformed the US Market which returned -11.7% over the past year.
|SONN Average Weekly Movement||11.4%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: SONN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: SONN's weekly volatility has decreased from 20% to 11% over the past year.
About the Company
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.
Sonnet BioTherapeutics Holdings Fundamentals Summary
|SONN fundamental statistics|
Is SONN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SONN income statement (TTM)|
|Cost of Revenue||US$19.06m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.45|
|Net Profit Margin||-3,876.87%|
How did SONN perform over the long term?See historical performance and comparison
Is SONN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SONN?
Other financial metrics that can be useful for relative valuation.
|What is SONN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SONN's PS Ratio compare to its peers?
|SONN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CYTH Cyclo Therapeutics
YMTX Yumanity Therapeutics
SONN Sonnet BioTherapeutics Holdings
Price-To-Sales vs Peers: SONN is expensive based on its Price-To-Sales Ratio (25.5x) compared to the peer average (13.5x).
Price to Earnings Ratio vs Industry
How does SONN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: SONN is expensive based on its Price-To-Sales Ratio (25.5x) compared to the US Biotechs industry average (16.5x)
Price to Sales Ratio vs Fair Ratio
What is SONN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||25.5x|
|Fair PS Ratio||0x|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate SONN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of SONN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SONN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SONN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Sonnet BioTherapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SONN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SONN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SONN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SONN's revenue is expected to decline over the next 3 years (-122.1% per year).
High Growth Revenue: SONN's revenue is forecast to decline over the next 3 years (-122.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SONN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Sonnet BioTherapeutics Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SONN is currently unprofitable.
Growing Profit Margin: SONN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SONN is unprofitable, and losses have increased over the past 5 years at a rate of 41.2% per year.
Accelerating Growth: Unable to compare SONN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SONN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: SONN has a negative Return on Equity (-322%), as it is currently unprofitable.
Discover strong past performing companies
How is Sonnet BioTherapeutics Holdings's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SONN's short term assets ($14.9M) exceed its short term liabilities ($6.5M).
Long Term Liabilities: SONN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SONN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SONN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SONN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SONN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 60.9% each year
Discover healthy companies
What is Sonnet BioTherapeutics Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SONN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SONN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SONN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SONN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SONN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pankaj Mohan (57 yo)
Dr. Pankaj Mohan, Ph.D. founded Sonnet BioTherapeutics Holdings, Inc. in 2015 and has since served as a member of its Board of Directors. Dr. Mohan has been Chairman of Sonnet BioTherapeutics Holdings, Inc...
CEO Compensation Analysis
Compensation vs Market: Pankaj's total compensation ($USD792.17K) is about average for companies of similar size in the US market ($USD763.69K).
Compensation vs Earnings: Pankaj's compensation has been consistent with company performance over the past year.
Experienced Management: SONN's management team is considered experienced (2.8 years average tenure).
Experienced Board: SONN's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 144.7%.
Sonnet BioTherapeutics Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Sonnet BioTherapeutics Holdings, Inc.
- Ticker: SONN
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$18.055m
- Shares outstanding: 60.59m
- Website: https://www.sonnetbio.com
Number of Employees
- Sonnet BioTherapeutics Holdings, Inc.
- 100 Overlook Center
- Suite 102
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/12 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.